Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has announced its first Investor R&D Day, set for January 28, 2022, from 9:00 a.m. to 11:30 a.m. Pacific Time. This virtual event aims to provide insights into its life science reagents and services, primarily for biotechnology and pharmaceutical innovations. Attendees can pre-register for the event, and a playback will be available afterward. Maravai continues to be a leader in providing products for drug therapies, diagnostics, and novel vaccines.
Maravai LifeSciences Holdings (NASDAQ: MRVI) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This key index tracks the performance of biotechnology and pharmaceutical companies listed on Nasdaq, reflecting their market activity. To qualify, companies must meet specific criteria such as market capitalization and trading volume. Maravai, a provider of life science reagents and services supporting drug development and diagnostics, demonstrates its growth potential through this milestone.
Summary not available.
Maravai LifeSciences (NASDAQ: MRVI) reported a significant 133% revenue increase, reaching $204.8 million for Q3 2021, compared to $87.9 million in Q3 2020. Net income surged 240% to $132.8 million. The company raised its 2021 revenue guidance to $770-$780 million and introduced preliminary 2022 guidance of $840-$880 million. Key growth was driven by Nucleic Acid Production, up 170% year-over-year. Maravai also closed the sale of its Protein Detection segment and published its inaugural Environmental, Social and Governance Report.
On November 8, 2021, New England Biolabs (NEB) announced the release of the HiScribe T7 mRNA Kit featuring TriLink's CleanCap Reagent AG. This new kit simplifies mRNA synthesis, offering high yields with a Cap 1 structure, enhancing biological activity while reducing immunogenicity. NEB's kits are scalable for therapeutic mRNA manufacturing, including vaccine production. The collaboration aims to accelerate research and development in mRNA technology. NEB continues to expand its offerings in molecular biology, supporting global vaccine programs.
Maravai LifeSciences (NASDAQ: MRVI) has announced its participation in two upcoming virtual investor conferences in November 2021. CFO Kevin Herde will engage in a fireside chat at the Stifel Healthcare Conference on November 17 at 10:20 a.m. PT and present at the Nasdaq Investor Conference on November 30 at 7:00 a.m. PT. Live webcasts will be available on the company's investor relations website, with archived versions posted shortly after each event. Maravai specializes in life science reagents and services, supporting drug therapy and diagnostics development.
Maravai LifeSciences (NASDAQ: MRVI) will announce its third quarter 2021 financial results after market close on November 10, 2021. A conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET the same day, which can be accessed by dialing (833) 693-0536 or (661) 407-1576 with conference ID 9136747. Participants can also listen via live or archived webcast on the company's Investors website. Maravai provides essential products for drug therapy, diagnostics, and vaccine development.
Maravai LifeSciences (NASDAQ: MRVI) has announced that its subsidiary, TriLink BioTechnologies, received a new European patent (No. 3352584) for its CleanCap technology, which enhances the production of synthetic mRNA. This patent is crucial for developing mRNA vaccines and therapeutics, facilitating a streamlined manufacturing process that reduces time and costs. Mike Houston, Chief Scientific Officer, highlighted the advantages of CleanCap in improving the efficiency and viability of mRNA constructs, particularly in rapid vaccine responses and personalized cancer therapies.
TriLink BioTechnologies announced its collaboration with EyeGene to supply its proprietary CleanCap® technology and modified uridine triphosphate for the production of EyeGene’s EG-COVID mRNA vaccine, which has received approval for clinical trials from South Korea's MFDS. This partnership marks a significant advancement in mRNA vaccine development, aiming to enhance safety and effectiveness. The vaccine will undergo Phase 1/2a trials, utilizing a cationic liposome delivery system.
Maravai LifeSciences Holdings (NASDAQ: MRVI) announced a public offering of 20 million shares at $50.00 each, set to close on September 14, 2021. The shares are being sold by certain stockholders, with a 30-day option for underwriters to purchase an additional 3 million shares. Maravai will not receive any proceeds from this sale. Key financial institutions such as Morgan Stanley, Jefferies, and Goldman Sachs are managing the offering. The registration statement was declared effective on September 9, 2021.